CYP2C9 and fungal infectious disease: Ruxolitinib is primarily metabolized by the cytochrome P450 (CYP450) enzymes, specifically CYP2C9 and CYP3A4.31,32 Azoles are potent CYP3A4 inhibitors and commonly used for prophylaxis or treatment of fungal infections during aGVHD treatment.